🔗 Share this article Patients Discontinuing Anti-Obesity Medications Gain Back Weight Far More Rapidly Compared to Dieters Weight management involves long-term strategies. New research indicates that patients who discontinue popular slimming jabs like Mounjaro or Wegovy may regain lost weight far faster than those who end conventional lifestyle plans. Published data in a leading health publication points out that while obese people frequently drop about a fifth of their total mass while using the jabs, the weight returns at an average rate of 0.8 kg per month after stopping. "Users buying these treatments must be aware of the risk of quick weight regain when the medication concludes," warns researcher Dr. Susan Jebb. This pace of recovery means a reversion to pre-treatment mass in about one and a half years. Comparing Therapies The research, which reviewed dozens of studies involving over 9,000 of patients, compared the outcomes of the injectable medications with older methods. Researchers note that people who lose weight through diet and exercise generally experience a more gradual weight regain—perhaps 0.1 kg a month—once they finish. The Reason for the Fast Rebound Doctors believe the mode of action of the injections is key to understanding the amplified weight return. The injections copy a body's own chemical called glucagon-like peptide-1, which moderates feelings of fullness. "Artificially providing the hormone concentrations several times higher than normal could lead to the body to generate a reduced amount of its endogenous hormone, and could lessen responsiveness to its actions," noted Dr. Adam Collins, a nutrition researcher. "Discontinuation of this GLP-1 'fix' means hunger is uncontrolled, making binge eating a significant risk." An Ongoing Condition? Medical guidelines advise the injections for individuals with weight-linked health risks, alongside prescribed lifestyle changes. Many experts argue that, due to the high risk of relapse, the treatment might need to be long-term. This view is supported by pharmaceutical companies, who say that the findings "highlight the long-term nature of obesity," akin to managing conditions like hypertension. Patient Experiences People who have come off the jabs report a intense resurgence of cravings. "I experienced something that goes on and I was suddenly starving," described a patient. This challenge is compounded if patients have not established lasting dietary or behavioural modifications during therapy. Growing Adoption Recent estimates indicate that a significant number of adults in the UK have used these injections in the past year, with desire being substantial. Use is more common among females compared to males. The 40s and 50s age group shows the greatest level of interest. A large proportion obtain the medications through private prescriptions rather than the NHS. Finally, researchers caution that while these medications are potent tools for weight loss, they are not a standalone cure and long-term success hinges on ongoing behavioural support.
Weight management involves long-term strategies. New research indicates that patients who discontinue popular slimming jabs like Mounjaro or Wegovy may regain lost weight far faster than those who end conventional lifestyle plans. Published data in a leading health publication points out that while obese people frequently drop about a fifth of their total mass while using the jabs, the weight returns at an average rate of 0.8 kg per month after stopping. "Users buying these treatments must be aware of the risk of quick weight regain when the medication concludes," warns researcher Dr. Susan Jebb. This pace of recovery means a reversion to pre-treatment mass in about one and a half years. Comparing Therapies The research, which reviewed dozens of studies involving over 9,000 of patients, compared the outcomes of the injectable medications with older methods. Researchers note that people who lose weight through diet and exercise generally experience a more gradual weight regain—perhaps 0.1 kg a month—once they finish. The Reason for the Fast Rebound Doctors believe the mode of action of the injections is key to understanding the amplified weight return. The injections copy a body's own chemical called glucagon-like peptide-1, which moderates feelings of fullness. "Artificially providing the hormone concentrations several times higher than normal could lead to the body to generate a reduced amount of its endogenous hormone, and could lessen responsiveness to its actions," noted Dr. Adam Collins, a nutrition researcher. "Discontinuation of this GLP-1 'fix' means hunger is uncontrolled, making binge eating a significant risk." An Ongoing Condition? Medical guidelines advise the injections for individuals with weight-linked health risks, alongside prescribed lifestyle changes. Many experts argue that, due to the high risk of relapse, the treatment might need to be long-term. This view is supported by pharmaceutical companies, who say that the findings "highlight the long-term nature of obesity," akin to managing conditions like hypertension. Patient Experiences People who have come off the jabs report a intense resurgence of cravings. "I experienced something that goes on and I was suddenly starving," described a patient. This challenge is compounded if patients have not established lasting dietary or behavioural modifications during therapy. Growing Adoption Recent estimates indicate that a significant number of adults in the UK have used these injections in the past year, with desire being substantial. Use is more common among females compared to males. The 40s and 50s age group shows the greatest level of interest. A large proportion obtain the medications through private prescriptions rather than the NHS. Finally, researchers caution that while these medications are potent tools for weight loss, they are not a standalone cure and long-term success hinges on ongoing behavioural support.